NeuroScientific Biopharmaceuticals Appoints Paul Rennie as interim CEO
- NeuroScientific Biopharmaceuticals (NSB) appoints Paul Rennie as interim CEO, nearly three months after former CEO Matt Liddelow resigned
- Paul Rennie is currently NSB’s Chair and will remain in both positions, but take more of an “active role” in management while the company searches for a permanent CEO
- Paul Rennie is also Chair and incoming Managing Director of ASX-listed Paradigm Pharmaceuticals (PAR) and will serve his roles with both companies concurrently
- Paradigm has a market cap of $441.7 million – nearly 30 times the size of NSB’s $14.3 million
- NSB shared were up 12.5 per cent, trading at 11.3 cents at 12:49 pm AEDT
